RVMD
NASDAQRevolution Medicines Inc.
Price$188.00-5.03 (-2.60%)
01:30 PM07:45 PM
News · 26 weeks102+40%
2026-04-122026-10-04
Mix4490d
- Insider18(41%)
- Other11(25%)
- SEC Filings11(25%)
- Earnings2(5%)
- Analyst2(5%)
Latest news
25 items- PRRevolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic CancerREDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 clinical trial evaluating the combination of RASONQUE (daraxonrasib), a RAS(ON) multi-selective inhibitor, and zoldonrasib, an investigational RAS(ON) G12D-selective inhibitor, as a first-line treatment in adult patients with metastatic RAS G12D pancreatic adenocarcinoma (PDAC). "RAS G12D is the most common RAS variant in PDAC," said Alan San
- INSIDERChief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERSVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDEROfficer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- PRKRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034SAN DIEGO, Sept. 28, 2026 /CNW/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected to account for nearly 70% of the total. As the first generation of RAS-targeted drugs gives way to broader multi-selective inhibitors, the field's central question
- INSIDERDirector Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- ANALYSTGoldman resumed coverage on Revolution Medicines with a new price targetGoldman resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $267.00
- INSIDEROfficer Mancini Anthony sold $347,402 worth of shares (1,764 units at $196.94) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 40,352 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERChief Development Officer Sandler Alan B. sold $67,941 worth of shares (341 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 52,868 units (SEC Form 4) to satisfy withholding tax4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDEROfficer Mancini Anthony sold $353,449 worth of shares (1,774 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 42,116 units (SEC Form 4) (for tax liability)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDEROfficer Kelsey Stephen Michael sold $1,109,554 worth of shares (5,569 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 286,307 units (SEC Form 4) to satisfy withholding obligation4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERChief Operating Officer Horn Margaret A sold $989,613 worth of shares (4,967 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 149,680 units (SEC Form 4) (withholding tax)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDEROfficer Goldsmith Mark A sold $2,786,938 worth of shares (13,988 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 253,342 units (SEC Form 4) (for withholding tax)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERSVP & General Counsel Cislini Jeff sold $670,631 worth of shares (3,366 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 52,541 units (SEC Form 4) (tax liability)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERChief Financial Officer Anders Jack sold $807,513 worth of shares (4,053 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 119,216 units (SEC Form 4) to satisfy withholding obligation4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- SECSEC Form 144 filed by Revolution Medicines Inc.144 - Revolution Medicines, Inc. (0001628171) (Subject)
- SECSEC Form 144 filed by Revolution Medicines Inc.144 - Revolution Medicines, Inc. (0001628171) (Subject)
- SECSEC Form 144 filed by Revolution Medicines Inc.144 - Revolution Medicines, Inc. (0001628171) (Subject)
- INSIDEROfficer Kelsey Stephen Michael exercised 92,531 shares at a strike of $41.71 and sold $18,724,767 worth of shares (92,531 units at $202.36) as part of a pre-agreed trading plan (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDEROfficer Mancini Anthony exercised 9,363 shares at a strike of $33.62 and sold $3,153,807 worth of shares (15,448 units at $204.16) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 43,890 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- PRRevolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic CancerCompany receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for patients with RAS-addicted cancers REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company’s RAS(ON) multi-selective inhibitor, for tre
- SECSEC Form 144 filed by Revolution Medicines Inc.144 - Revolution Medicines, Inc. (0001628171) (Subject)
- INSIDERDirector Kim Lorence H. sold $3,585,837 worth of shares (17,090 units at $209.82) as part of a pre-agreed trading plan (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- ANALYSTMorgan Stanley initiated coverage on Revolution Medicines with a new price targetMorgan Stanley initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $255.00
- PRNew England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung CancerResults support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS mutant non-small cell lung cancer (NSCLC)
RVMD FAQ
7 questionsWhat does Revolution Medicines Inc. do?
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a...Where does RVMD stock trade?
Revolution Medicines Inc. (RVMD) is listed on NASDAQ.What sector and industry is RVMD in?
Revolution Medicines Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Revolution Medicines Inc. go public?
Revolution Medicines Inc. (RVMD) completed its IPO in 2020.What are analysts saying about RVMD?
Revolution Medicines Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy on 2026-09-24.What companies are similar to RVMD?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), BIIB (Biogen Inc.). Compare RVMD side-by-side with any of them on Quantisnow.How can I track RVMD on Quantisnow?
Quantisnow aggregates Revolution Medicines Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RVMD to receive live email and push alerts on every new disclosure.